Lesson plan
Vanoglipel
Vanoglipel ( ), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.
Article summary
Vanoglipel ( ), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.